
A study on once-weekly semaglutide 2.4 mg in cardiovascular patients with overweight or obesity found a lower incidence of serious adverse events compared to placebo. While gastrointestinal issues led to more discontinuations, no new safety concerns emerged. The findings reaffirm semaglutide's established safety profile, supporting its role in cardiovascular and weight management.
Like
Save
Share